Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Holding CTMX?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.2Last Year’s EPS
$0.02Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 9.00%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced sentiment. While there were significant achievements in revenue growth, pipeline progress, and strong collaborations, there were also concerns over increased expenses and delays in key clinical decisions.Company Guidance
During CytomX Therapeutics' Q3 2024 earnings call, the company provided guidance on its advancing pipeline and financial health. The discussion highlighted three key programs: CX-904, CX-2051, and CX-801. CX-904, a Probody T-cell engager targeting EGFR and CD3, is in dose escalation, having reached a 15-milligram step without a maximum tolerated dose identified. Meanwhile, CX-2051, an EpCAM-directed antibody drug conjugate, is progressing swiftly in Phase I, enrolling its fifth dose cohort and showing promising safety data. The company also initiated the Phase I trial for CX-801, aiming for initial data by late 2025. Financially, CytomX reported Q3 revenue of $33.4 million, up from $26.4 million the previous year, driven by collaborations with Bristol-Myers Squibb and Moderna. Operating expenses rose to $29.3 million due to increased R&D spending, with cash reserves projected to fund operations through 2025. These efforts underscore CytomX's strategic focus on advancing its platform of masked, conditionally activated biologics to address high unmet needs in oncology.Increased Revenue
Revenue for Q3 2024 was $33.4 million, a significant increase from $26.4 million in Q3 2023, driven by collaborations with Bristol-Myers Squibb and Moderna.
Advancements in CX-904
CX-904 has shown favorable safety profile and encouraging early signs of anticancer activity. The 15-milligram dose cohort has cleared without reaching a maximum tolerated dose, indicating potential for further escalation.
Progress with CX-2051
Dose escalation for CX-2051 is progressing well, with the fifth cohort underway, demonstrating a favorable safety profile. This program targets a large potential market with an estimated 300,000 EpCAM-positive patients in the U.S.
Pipeline Expansion and Collaborations
CytomX has more than 15 active discovery and development programs, with strong partnerships with Amgen, Astellas, BMS, Moderna, and Regeneron, focusing on masked T-cell engagers.
Financial Stability
CytomX ended Q3 2024 with $118 million in cash, with expectations to fund operations through the end of 2025.
---
CTMX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CTMX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $1.00 | $1.09 | +9.00% |
| Aug 08, 2024 | $1.18 | $1.20 | +1.69% |
| May 08, 2024 | $4.19 | $2.04 | -51.31% |
| Mar 11, 2024 | $2.51 | $2.15 | -14.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CytomX Therapeutics Inc (CTMX) report earnings?
CytomX Therapeutics Inc (CTMX) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is CytomX Therapeutics Inc (CTMX) earnings time?
CytomX Therapeutics Inc (CTMX) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTMX EPS forecast?
CTMX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.2.
---